Full text is available at the source.
Cardiovascular efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: a systematic review and network meta‐analysis
Heart benefits and safety of two diabetes drug types: sodium-glucose blockers and GLP-1 receptor activators
AI simplified
Abstract
In a network meta-analysis of eight trials involving 60,082 participants, both SGLT2 inhibitors and GLP-1 receptor agonists reduced the risk of major adverse cardiovascular events compared to placebo.
- SGLT2 inhibitors and GLP-1 receptor agonists both showed a reduction in the three-point composite measure of major adverse cardiovascular events.
- The hazard ratio for SGLT2 inhibitors was 0.86, while for GLP-1 receptor agonists it was 0.88, indicating a similar level of efficacy.
- There were no significant differences in cardiovascular outcomes between SGLT2 inhibitors and GLP-1 receptor agonists.
- SGLT2 inhibitors significantly reduced the risk of hospital admission for heart failure compared to placebo (hazard ratio 0.67) and GLP-1 receptor agonists (hazard ratio 0.71).
- No differences were observed between the two drug classes regarding non-fatal stroke, non-fatal myocardial infarction, cardiovascular mortality, all-cause mortality, or safety outcomes.
AI simplified